The anti-PCSK9 monoclonal antibodies, evolocumab and alirocumab, should be initiated if maximum intense statins and ezetimibe fail to sufficiently control the lipid profile in FH cases with a major risk of cardiomyopathies [6]. The gene discussed is PCSK9; the disease is familial hyperaldosteronism.